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Dendritic cells (DC) are acknowledged to be quintessen-
tial in the armamentarium to mount anti-tumor immune
responses and have been utilized in varying capacities for
cancer immunotherapy. Recent advancements & lessons
leant from prior DC therapies have revealed that major
barriers hinder the efficacy of cancer vaccination with
DC, principal of which is the hostile environment of the
local tumor milieu that inhibits activation and subse-
quent maturation of DC. This critical step is required to
process and present antigens (tumor cell) to the down-
stream cascade of immune mediators. The therapeutic
goals of cancer vaccination are the induction of tumor
regression secondary to the production of tumor specific
immune factors and local inflammatory cytokines with
enhancement of long term anti-tumor surveillance to
prevent recurrences. DCVax®- Direct (Northwest
Biotherapeutics, Inc. Bethesda, MD) are autologous den-
dritic cells activated Ex vivo with BCG and IFNg for
intratumoral injection and attempts to circumvent this
barrier thereby maximize the induction of anti-tumor
responses. Autologous DC will be harvested from peri-
pheral blood monocytes via leukapheresis. Following
Ex vivo DC maturation, inoculation of the tumors will be
performed 2 weeks later utilizing image guidance to
ensure activated DC deposition at the peripheral aspect
of the tumor thereby enhancing DC exposure to antigens
from dead or dying tumor cells. Vaccination will be per-
formed at least every week for 3 weeks, and subsequently
at longer intervals dependent on harvested DC avail-
ability. Phase I/II study with DCVax®- Direct will enable
evaluation of the safety, MTD, and responses in patients
with solid tumors. The secondary objective addresses the
feasibility, anti-tumor immune responses, PFS and OS.
At the time of this poster submission, the ‘First-in-man’
patient has been consented for the study. We propose to
present our initial findings at the SITC 2013 conference
as more data will be available.
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